Non-Small Cell Lung Cancer Treatment - National Cancer Institute
Links shared publicly online about this topic.
- 1,291total visits
Non-Small Cell Lung Cancer Treatment - National Cancer Institute
View full resource at cancer.gov
Tags: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Lung, Disease and Condition, Oncology
Most Recently Shared on March 24, 2010 at 10:20 pm By:
Non-small cell lung #cancer is a disease in which malignant (cancer) cells form in the tissues of the lung http://bit.ly/d7mzDq #oncology
Study assesses link between antifolate medications, KRAS mutations and amplification
news-medical.net — “Testing patients with non-small cell lung cancer for both mutations and amplifications of the KRAS gene prior to therapy may help to predict response to treatment with antifolates, according to the updated results of a preclinical study presented at the AACR Annual Meeting 2012, held here March 31 - April 4.” View full resource at news-medical.net
Most Recently Shared on April 5, 2012 at 11:29 am By:
Lung Cancer News: Study assesses link between antifolate medications, KRAS mutations and amplification: Testing ... http://t.co/pTIigUcV
Combination treatment shows promise against NSCLC patients ineligible for bevacizumab
news-medical.net — “A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.” View full resource at news-medical.net
Most Recently Shared on April 4, 2012 at 11:27 am By:
Lung Cancer News: Combination treatment shows promise against NSCLC patients ineligible for bevacizumab: A combi... http://t.co/vU5W9EYs
Clovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibitor CO-1686 - Yahoo! News
news.yahoo.com — “From Yahoo! News: Clovis Oncology, Inc. (Nasdaq: CLVS) announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer (NSCLC).” View full resource at news.yahoo.com
Most Recently Shared on March 28, 2012 at 11:04 am By:
Clovis Oncology Announces Enrollment of First Patient in First Human Study of Oral EGFR Mutant-Selective Inhibit... http://t.co/48JzhFAO
Combining RNA Interference With Tyrosine Kinase Inhibitors Or Cetuximab Enhances Lung Cancer Therapy
medicalnewstoday.com — “Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with t” View full resource at medicalnewstoday.com
Most Recently Shared on March 21, 2012 at 8:05 am By:
Combining RNA Interference With Tyrosine Kinase Inhibitors Or Cetuximab Enhances Lung Cancer Therapy: Non-small ... http://t.co/nfOz9EY5
Double whammy: RNAi enhances lung cancer therapy
medicalxpress.com — “Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is usually treated with surgery and chemotherapy. However, a small group of patients can also be helped by treatment with tyrosine kinase inhibitors (TKI). New research published in BioMed Central's open access journal BMC Medicine, ...” View full resource at medicalxpress.com
Most Recently Shared on March 20, 2012 at 11:57 pm By:
PhysOrg Health News Health News
Double whammy: RNAi enhances lung cancer therapy http://t.co/EN8Gv6zW
Symposier - Pasi Janne on new lung and colorectal cancer gene discovery | Dana-Farber Cancer Institute
symposier.com — “Uploaded and shared in Youtube by: DanaFarberCancerInst — The new frontier of cancer treatment, personalized medicine, involves identifying specific genetic abnormalities in cancerous cells and targeting them with drugs that are most likely to cause an effective response. Pasi Janne, MD, PhD, discusses the discovery that some types of non-small cell lung cancer and colorectal cancer share similar genetic abnormalities with cancers that are known to respond to targeted therapies, and explains how” View full resource at symposier.com
Most Recently Shared on March 15, 2012 at 4:17 pm By:
Newly identified fusion genes in lung and colorectal cancer may guide treatment with 'targeted' drugs. http://t.co/THab6dZe
CME: Tailoring Treatment Plans to Improve Survival in Non-Small Lung Cancer - OncologySTAT
oncologystat.com — “Free Online Medical CME Course Credits: Tailoring Treatment Plans to Improve Survival in Non-Small Lung Cancer” View full resource at oncologystat.com
Most Recently Shared on March 15, 2012 at 3:38 pm By:
OncologySTAT Health Site and Oncology
CME Program: Tailoring Treatment Plans to Improve Survival in Non-Small Cell Lung Cancer http://t.co/1TjvHei1
Gene sequencing could identify genetic variants of lung cancer and colorectal cancer
news-medical.net — “Foundation Medicine Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute have come up with the results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.” View full resource at news-medical.net
Most Recently Shared on February 14, 2012 at 7:36 pm By:
News-Medical.Net Oncology and Health News
Oncology News: Gene sequencing could identify genetic variants of lung cancer and colorectal cancer: Foundation ... http://t.co/vJ53MF0V
Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer
news-medical.net — “Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.” View full resource at news-medical.net
Most Recently Shared on February 13, 2012 at 4:43 pm By:
Lung Cancer News: Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer: Fo... http://t.co/R0aH0W7O
Battling Lung Cancer With Combination Drug Therapy
medicalnewstoday.com — “Combination drug therapy may be needed to combat non-small cell lung cancer (NSCLC), according to a study by the Translational Genomics Research Institute (TGen) and Van Andel Research Institute (” View full resource at medicalnewstoday.com
Most Recently Shared on February 5, 2012 at 8:05 am By:
Battling Lung Cancer With Combination Drug Therapy http://t.co/prmuBl3G #lungcancer
Erlotinib better for treatment of non-small cell lung cancers associated with altered forms of EGFR protein
news-medical.net — “Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer's cells resistant to cancer drugs.” View full resource at news-medical.net
Most Recently Shared on January 11, 2012 at 12:38 pm By:
Lung Cancer News: Erlotinib better for treatment of non-small cell lung cancers associated with altered forms of... http://t.co/eIX5kRzW
Syndax Pharmaceuticals, Ventana Medical Systems to Develop Companion Diagnostic Test for Lung Cancer | IVD Technology
ivdtechnology.com — “Syndax Pharmaceuticals Inc. and Ventana Medical Systems Inc. have entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and Syndax’s proprietary lead molecule entinostat.” View full resource at ivdtechnology.com
Most Recently Shared on January 9, 2012 at 7:42 pm By:
IVD Technology Health Magazine
Syndax Pharmaceuticals, Ventana Medical Systems to Develop Companion Diagnostic Test for Lung Cancer http://t.co/qVXrItLx
Symposier - Dr. Belani Discusses NSCLC Adjuvant Therapy
symposier.com — “Uploaded and shared in Youtube by: OncLiveTV — Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey Medical Center & College of Medicine, discusses recent changes to adjuvant therapy for non-small cell lung cancer (NSCLC). Adjuvant therapy is the current standard of care for patients with resectable NSCLC. Various trials have suggested that the absolute improvement in overall survival from adjuvant tre” View full resource at symposier.com
Most Recently Shared on January 4, 2012 at 5:56 pm By:
Recent changes to adjuvant therapy for non-small cell lung cancer (NSCLC). http://t.co/maBnxPAJ
Roche's Cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark
medicalnewstoday.com — “Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the cobas EGFR Mutation Test is now CE marked for commercial availability in Europe and other countries that recognize CE mark. The cobas EGFR Mu” View full resource at medicalnewstoday.com
Most Recently Shared on December 2, 2011 at 9:05 am By:
Roche's Cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark http://t.co/E97KXFFy #lungcancer
Therapy for Elderly Patients with Non-Small Cell Lung Cancer Part 1: Systemic Therapy
secure.quantiamd.com — “Learn about therapies that work in both elderly and young patients from NCCN Non-Small Cell Lung Cancer Panel, Guidelines Steering Committee member Wallace Akerley, MD, Co-Director of the Thoracic Cancer Program, Huntsman Cancer Institute (HCI)” View full resource at secure.quantiamd.com
Most Recently Shared on October 20, 2011 at 2:20 pm By:
QuantiaMD Support and Health Social Media
Therapy for Elderly Patients with Non-Small Cell Lung Cancer. Therapies that work in both elderly & young patients http://t.co/xAF4kA2G #CME
Advertisement
